Pharmacogenetic issues in thorough QT trials

Molecular Diagnosis and Therapy

Volumn 10, Issue 3, 2006, Pages 153-162

  Judson, Richard S ^a   Salisbury, Benjamin A ^b,d   Reed, Carol R ^b   Ackerman, Michael J ^c  

^a SpyroPharma   (United States)

^b Clinical Data Inc   (United States)

^c Mayo Clinic   (United States)

^d Clinical Data Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISAPRIDE; CYTOCHROME P450; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; POTASSIUM CHANNEL; POTASSIUM CHANNEL HERG; SOTALOL; TERFENADINE;

DRUG HYPERSENSITIVITY; DRUG INDUCED DISEASE; DRUG METABOLISM; DRUG WITHDRAWAL; GENE MUTATION; HEREDITY; HUMAN; PHARMACOGENETICS; PRIORITY JOURNAL; QT PROLONGATION; REVIEW; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 33745668444     PISSN: 11771062     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03256454     Document Type: Review

References (76)

1. ICH Harmonised Tripartite Guideline. The clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs. ICH E14 [online]. Available from URL: http://www.ich.org [Accessed 2006 May 2]
2. Camm AJ, Malik M, Yee GY. Acquired long QT syndrome. Malden (MA): Futura/Blackwell, 2004
3. Anson BD, Weaver JG, Ackerman MJ, et al. Blockade of HERG channels by HIV protease inhibitors. Lancet 2005 Feb 19; 365 (9460): 682-6
4. Shah RR. Pharmacogenetic aspects of drug-induced torsade de pointes: potential tool for improving clinical drug development and prescribing. Drug Saf 2004; 27 (3): 145-72
5. Ackerman MJ. Cardiac channelopathies: it's in the genes. Nat Med 2004 May; 10 (5): 463-4
6. Bednar MM, Harrigan EP, Anziano RJ, et al. The QT interval. Prog Cardiovasc Dis 2001 Mar; 43 (5 Suppl. 1): 1-45
7. Committee for Proprietary Medicinal Products. Points to consider: the assessment of the potential for QT prolongation by non-cardiovascular medicinal products. London: The European Agency for the Evaluation of Medicinal Products, 1997
8. Priori SG, Schwartz PJ, Napolitano C, et al. Risk stratification in the long-QT syndrome. N Engl J Med 2003 May 8; 348 (19): 1866-74
9. Woosley RL, Sale M. QT interval: a measure of drug action. Am J Cardiol 1993 Aug 26; 72 (6): 36B-43B
10. Moss AJ, Schwartz PJ. Delayed repolarization (QT or QTU prolongation) and malignant ventricular arrhythmias. Mod Concepts Cardiovasc Dis 1982 Mar; 51 (3): 85-90
11. Roden DM. Taking the "idio" out of "idiosyncratic": predicting torsades de pointes. Pacing Clin Electrophysiol 1998 May; 21 (5): 1029-34
12. Roden DM. Drug-induced prolongation of the QT interval. N Engl J Med 2004 Mar 4; 350 (10): 1013-22
13. Judson R, Moss A. Pharmacogenomics in drug development: when and how to apply. In: Morganroth J, Gussak I, editors. Cardiac safety of non-cardiac drugs: practical guidelines for clinical research and drug development. Totowa (NJ): Humana Press, 2005: 83-103
14. Wysowski DK, Corken A, Gallo-Torres H, et al. Postmarketing reports of QT prolongation and ventricular arrhythmia in association with cisapride and Food and Drug Administration regulatory actions. Am J Gastroenterol 2001 Jun; 96 (6): 1698-703
15. Monahan BP, Ferguson CL, Killeavy ES, et al. Torsades de pointes occurring in association with terfenadine use. JAMA 1990 Dec 5; 264 (21): 2788-90
16. Hohnloser SH. Proarrhythmia with class III antiarrhythmic drugs: types, risks, and management. Am J Cardiol 1997 Oct 23; 80 (8A): 82G-9G
17. Kirchheiner J, Brosen K, Dahl ML, et al. CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants: a first step towards subpopulation-specific dosages. Acta Psychiatr Scand 2001 Sep; 104 (3): 173-92
18. Thummel KE, Wilkinson GR. In vitro and in vivo drug interactions involving human CYP3A. Annu Rev Pharmacol Toxicol 1998; 38: 389-430
19. Fujita K. Food-drug interactions via human cytochrome P450 3A (CYP3A). Drug Metabol Drug Interact 2004; 20 (4): 195-217
20. Carlson AM, Morris LS. Coprescription of terfenadine and erythromycin or ketaconazole: an assessment of potential harm. J Am Pharm Assoc (Wash) 1996 Apr; NS36 (4): 263-9
21. Thompson D, Oster G. Use of terfenadine and contraindicated drugs. JAMA 1996 May 1; 275 (17): 1339-41
22. Curtis LH, Ostbye T, Sendersky V, et al. Prescription of QT-prolonging drugs in a cohort of about 5 million outpatients. Am J Med 2003 Feb 1; 114 (2): 135-41
23. Roe CM, Odell KW, Henderson RR. Concomitant use of antipsychotics and drugs that may prolong the QT interval. J Clin Psychopharmacol 2003 Apr; 23 (2): 197-200
24. Priori SG. Exploring the hidden danger of noncardiac drugs. J Cardiovasc Electrophysiol 1998 Oct; 9 (10): 1114-6
25. Tester DJ, Will ML, Haglund CM, et al. Compendium of cardiac channel mutations in 541 consecutive unrelated patients referred for long QT syndrome genetic testing. Heart Rhythm 2005 May; 2 (5): 507-17
26. Priori SG, Napolitano C, Schwartz PJ. Low penetrance in the long-QT syndrome: clinical impact. Circulation 1999 Feb 2; 99 (4): 529-33
27. Prevalence of the long QT syndrome [abstract no. 3097]. In: 2005 Annual American Heart Association Meeting: Circulation 2005
28. Priori SG, Napolitano C. Genetic defects of cardiac ion channels: the hidden substrate for torsades de pointes. Cardiovasc Drugs Ther 2002 Mar; 16 (2): 89-92
29. Yang P, Kanki H, Drolet B, et al. Allelic variants in long-QT disease genes in patients with drug-associated torsades de pointes. Circulation 2002 Apr 23; 105 (16): 1943-8
30. Donger C, Denjoy I, Berthet M, et al. KVLQT1 C-terminal missense mutation causes a forme fruste long-QT syndrome. Circulation 1997 Nov 4; 96 (9): 2778-81
31. Napolitano C, Schwartz PJ, Brown AM, et al. Evidence for a cardiac ion channel mutation underlying drug-induced QT prolongation and life-threatening arrhythmias. J Cardiovasc Electrophysiol 2000 Jun; 11 (6): 691-6
32. Roden DM, Woosley RL, Primm RK. Incidence and clinical features of the quinidine-associated long QT syndrome: implications for patient care. Am Heart J 1986 Jun; 111 (6): 1088-93
33. Zehender M, Hohnloser S, Just H. QT-interval prolonging drugs: mechanisms and clinical relevance of their arrhythmogenic hazards. Cardiovasc Drugs Ther 1991 Apr; 5 (2): 515-30
34. Abbott GW, Sesti F, Splawski I, et al. MiRP1 forms IKr potassium channels with HERG and is associated with cardiac arrhythmia. Cell 1999 Apr 16; 97 (2): 175-87
35. Sesti F, Abbott GW, Wei J, et al. A common polymorphism associated with antibiotic-induced cardiac arrhythmia. Proc Natl Acad Sci U S A 2000 Sep 12; 97 (19): 10613-8
36. Jongbloed R, Marcelis C, Velter C, et al. DHPLC analysis of potassium ion channel genes in congenital long QT syndrome. Hum Mutat 2002 Nov; 20 (5): 382-91
37. Makita N, Horie M, Nakamura T, et al. Drug-induced long-QT syndrome associated with a subclinical SCN5A mutation. Circulation 2002 Sep 3; 106 (10): 1269-74
38. Seebohm G, Chen J, Strutz N, et al. Molecular determinants of KCNQ1 channel block by a benzodiazepine. Mol Pharmacol 2003 Jul; 64 (1): 70-7
39. Abitbol I, Peretz A, Lerche C, et al. Stilbenes and fenamates rescue the loss of I (KS) channel function induced by an LQT5 mutation and other IsK mutants. EMBO J 1999 Aug 2; 18 (15): 4137-48
40. Mitcheson JS, Chen J, Lin M, et al. A structural basis for drug-induced long QT syndrome. Proc Natl Acad Sci U S A 2000 Oct 24; 97 (22): 12329-33
41. Mitcheson JS, Chen J, Sanguinetti MC. Trapping of a methanesulfonanilide by closure of the HERG potassium channel activation gate. J Gen Physiol 2000 Mar; 115 (3): 229-40
42. Ficker E, Obejero-Paz CA, Zhao S, et al. The binding site for channel blockers that rescue misprocessed human long QT syndrome type 2 ether-a-gogo-related gene (HERG) mutations. J Biol Chem 2002 Feb 15; 277 (7): 4989-98
43. Lees-Miller JP, Duan Y, Teng GQ, et al. Molecular determinant of high-affinity dofetilide binding to HERG1 expressed in Xenopus oocytes: involvement of S6 sites. Mol Pharmacol 2000 Feb; 57 (2): 367-74
44. Haverkamp W, Breithardt G, Camm AJ, et al. The potential for QT prolongation and pro-arrhythmia by non-anti-arrhythmic drugs: clinical and regulatory implications. Report on a Policy Conference of the European Society of Cardiology. Cardiovasc Res 2000 Aug; 47 (2): 219-33
45. Roti EC, Myers CD, Ayers RA, et al. Interaction with GM130 during HERG ion channel trafficking: disruption by type 2 congenital long QT syndrome mutations: human Ether-a-go-go-related gene. J Biol Chem 2002 Dec 6; 277 (49): 47779-85
46. Valdivia CR, Tester DJ, Rok BA, et al. A trafficking defective, Brugada syndrome-causing SCN5A mutation rescued by drugs. Cardiovasc Res 2004 Apr 1; 62 (1): 53-62
47. Anderson CL, Delisle BP, Anson BD, et al. Most LQT2 mutations reduce Kv11.1 (hERG) current by a class 2 (trafficking-deficient) mechanism. Circulation 2006 Jan 24; 113 (3): 365-73
48. El Sherif N, Caref EB, Yin H, et al. The electrophysiological mechanism of ventricular arrhythmias in the long QT syndrome: tridimensional mapping of activation and recovery patterns. Circ Res 1996 Sep; 79 (3): 474-92
49. Akar FG, Yan GX, Antzelevitch C, et al. Unique topographical distribution of M cells underlies reentrant mechanism of torsade de pointes in the long-QT syndrome. Circulation 2002 Mar 12; 105 (10): 1247-53
50. Shimizu W, McMahon B, Antzelevitch C. Sodium pentobarbital reduces transmural dispersion of repolarization and prevents torsades de Pointes in models of acquired and congenital long QT syndrome. J Cardiovasc Electrophysiol 1999 Feb; 10 (2): 154-64
51. Keating MT, Sanguinetti MC. Molecular and cellular mechanisms of cardiac arrhythmias. Cell 2001 Feb 23; 104 (4): 569-80
52. Liu DW, Antzelevitch C. Characteristics of the delayed rectifier current (IKr and IKs) in canine ventricular epicardial, midmyocardial, and endocardial myocytes: a weaker IKs contributes to the longer action potential of the M cell. Circ Res 1995 Mar; 76 (3): 351-65
53. Houltz B, Darpo B, Edvardsson N, et al. Electrocardiographic and clinical predictors of torsades de pointes induced by almokalant infusion in patients with chronic atrial fibrillation or flutter: a prospective study. Pacing Clin Electrophysiol 1998 May; 21 (5): 1044-57
54. Bezzina CR, Verkerk AO, Busjahn A, et al. A common polymorphism in KCNH2 (HERG) hastens cardiac repolarization. Cardiovasc Res 2003 Jul 1; 59 (1): 27-36
55. Crotti L, Lundquist AL, Pedrazzini M, et al. Common KCNH2 polymorphism (K897T) as a genetic modifier of congenital long QT syndrome [abstract]. Heart Rhythm 2005 May; 2 (5 Suppl.): S111
56. Kannankeril PJ, Norris KJ, Gillani N, et al. A common polymorphism in KCNH2 (HERG) eliminates gender differences in drug-induced QT prolongation [abstract]. Heart Rhythm 2005 May; 2 (5 Suppl.): S145
57. Sun Z, Milos PM, Thompson JF, et al. Role of a KCNH2 polymorphism (R1047 L) in dofetilide-induced Torsades de Pointes. J Mol Cell Cardiol 2004 Nov; 37 (5): 1031-9
58. Splawski I, Timothy KW, Tateyama M, et al. Variant of SCN5A sodium channel implicated in risk of cardiac arrhythmia. Science 2002 Aug 23; 297 (5585): 1333-6
59. George Jr AL, Roden DM. Method for screening for susceptibility to drug-induced cardiac arrhythmia. US patent 6,458,542 B1. 2002
60. Westenskow P, Splawski I, Timothy KW, et al. Compound mutations: a common cause of severe long-QT syndrome. Circulation; Epub 2004 Mar 29109 (15): 1834-41
61. Salisbury BA, Judson RS, Pungliya MS, et al. The single nucleotide polymorphism D85N-KCNE1 is associated with both congenital and drug-induced Long QT [abstract]. Heart Rhythm 2006; 3 (5 Suppl.): S98
62. Paulussen AD, Gilissen RA, Armstrong M, et al. Genetic variations of KCNQ1, KCNH2, SCN5A, KCNE1, and KCNE2 in drug-induced long QT syndrome patients. J Mol Med 2004 Mar; 82 (3): 182-8
63. Wei J, Yang IC, Tapper AR, et al. KCNE1 Polymorphism confers risk of drug-induced long QT syndrome by altering kinetics of IKs potassium channels. Circulation 1999; 100 Suppl. I: 495
64. El Sherif N, Caref EB, Chinushi M, et al. Mechanism of arrhythmogenicity of the short-long cardiac sequence that precedes ventricular tachyarrhythmias in the long QT syndrome. J Am Coll Cardiol 1999 Apr; 33 (5): 1415-23
65. Kanki H, Yang P, Xie HG, et al. Polymorphisms in beta-adrenergic receptor genes in the acquired long QT syndrome. J Cardiovasc Electrophysiol 2002 Mar; 13 (3): 252-6
66. Marx SO, Kurokawa J, Reiken S, et al. Requirement of a macromolecular signaling complex for beta adrenergic receptor modulation of the KCNQ1-KCNE1 potassium channel. Science 2002 Jan 18; 295 (5554): 496-9
67. Piippo K, Swan H, Pasternack M, et al. A founder mutation of the potassium channel KCNQ1 in long QT syndrome: implications for estimation of disease prevalence and molecular diagnostics. J Am Coll Cardiol 2001 Feb; 37 (2): 562-8
68. Hara M, Danilo P, Rosen MR. Effects of gonadal steroids on ventricular repolarization and on the response to E4031. J Pharmacol Exp Ther 1998 Jun; 285 (3): 1068-72
69. Rodriguez I, Kilborn MJ, Liu XK, et al. Drug-induced QT prolongation in women during the menstrual cycle. JAMA 2001 Mar 14; 285 (10): 1322-6
70. Stramba-Badiale M, Locati EH, Martinelli A, et al. Gender and the relationship between ventricular repolarization and cardiac cycle length during 24-h Holter recordings. Eur Heart J 1997 Jun; 18 (6): 1000-6
71. Rashba EJ, Zareba W, Moss AJ, et al. Influence of pregnancy on the risk for cardiac events in patients with hereditary long QT syndrome. LQTS Investigators. Circulation 1998 Feb 10; 97 (5): 451-6
72. Khositseth A, Tester DJ, Will ML, et al. Identification of a common genetic substrate underlying postpartum cardiac events in congenital long QT syndrome. Heart Rhythm 2004 May; 1 (1): 60-4
73. Drici MD, Burklow TR, Haridasse V, et al. Sex hormones prolong the QT interval and downregulate potassium channel expression in the rabbit heart. Circulation 1996 Sep 15; 94 (6): 1471-4
74. Burke JH, Goldberger JJ, Ehlert FA, et al. Gender differences in heart rate before and after autonomic blockade: evidence against an intrinsic gender effect. Am J Med 1996 May; 100 (5): 537-43
75. Ackerman MJ, Tester DJ, Jones GS, et al. Ethnic differences in cardiac potassium channel variants: implications for genetic susceptibility to sudden cardiac death and genetic testing for congenital long QT syndrome. Mayo Clin Proc 2003 Dec; 78 (12): 1479-87
76. Ackerman MJ, Splawski I, Makielski JC, et al. Spectrum and prevalence of cardiac sodium channel variants among black, white, asian and hispanic individuals: implications for arrhythmogenic susceptibility and Brugada/Long QT syndrome genetic testing. Heart Rhythm J 2004 Nov; 1 (5): 600-7